Moderna's combined COVID and flu vaccine shows positive results

Moderna's phase 3 trial for a combined COVID and flu vaccine showed positive results with roughly 8,000 participants. The vaccine, mRNA-1083, elicited a strong immune response against COVID and three influenza strains. Safety was well-tolerated with common side effects. Combination vaccines offer advantages like cost reduction and increased vaccination uptake. The vaccine could be a crucial tool in increasing coverage against COVID and the flu, benefiting public health and the economy.